Welcome to our dedicated page for Dolby Laboratories SEC filings (Ticker: DLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dolby Laboratories filings document the regulatory disclosures of a technology licensing and cinema-products company whose Class A common stock trades on the New York Stock Exchange under DLB. Recent Form 8-K reports furnish quarterly and annual financial results, dividend declarations for Class A and Class B common stock, and related exhibits.
The company’s proxy and governance filings cover director elections, advisory executive-compensation votes, auditor ratification and executive incentive compensation arrangements. The filings also describe Dolby’s dual-class voting structure, with Class A and Class B common stock voting together on most stockholder matters except where law requires otherwise.
Dolby Laboratories (DLB) Form 144 shows a proposed sale of 25,000 common shares through Morgan Stanley Smith Barney on 08/12/2025 with an aggregate market value of $1,807,827.50. The filing lists 95,844,185 shares outstanding, and the securities were acquired the same day by stock option exercise with payment in cash. The notice also records multiple recent sales by Yeaman Family Trust between 06/10/2025 and 07/16/2025 in several tranches. By signing, the seller represents they are not aware of any undisclosed material adverse information; a Rule 10b5-1 plan date is not indicated.
Dolby Laboratories (NYSE:DLB) CEO Kevin Yeaman filed a Form 4 for transactions on 06/24/2025.
- Exercised 25,000 options at $45.50.
- Immediately sold the same 25,000 Class A shares at a weighted-average $74.02, generating ≈$1.85 million in gross proceeds.
- Sale represents about 18 % of the shares held in his family trust.
- Post-trade holdings: 114,725 Class A shares (trust), 127,735 unvested RSUs, and 135,615 unexercised options.
The trades were executed under a Rule 10b5-1 plan; no additional corporate events were disclosed.
Dolby Laboratories (DLB) insider filing reports planned sale of 25,000 shares of common stock with an aggregate market value of $1,850,530. The securities were acquired through a stock option exercise on June 24, 2025, and are planned to be sold through Morgan Stanley Smith Barney LLC on the NYSE.
The filing also discloses recent trading activity by the Yeaman Family Trust, which sold:
- 25,000 shares for gross proceeds of $1,905,650 on June 10, 2025
- 8,683 shares for gross proceeds of $661,829 on June 10, 2025
This Form 144 represents a notice of proposed sale of securities pursuant to Rule 144 under the Securities Act of 1933. The total shares to be sold represent approximately 0.026% of Dolby's outstanding shares (96,066,188 shares).